PBAC's latest decision on Netupitant/palonosetron: Recommended with restriction (2015). Considered for Prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients treated with highly emetogenic chemotherapy for malignancy, and in breast cancer patients treated with anthracycline plus cyclophosphamide based regimens.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2015
Submissions
2
2015 → 2015
Eligible population
Adult patients scheduled to receive highly emetogenic chemotherapy for malignancy, and breast cancer patients scheduled to receive anthracycline plus cyclophosphamide based regimens, in combination with dexamethasone.
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Complete response (acute, delayed, and overall nausea and vomiting)
Pivotal trial size
2,803 patients
Key trials
NETU-07-07, NETU-10-29, NETU-08-18, Trial 071
Comparator
aprepitant plus 5-HT3 receptor antagonist
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis presented; no ICER calculated. PBAC considered the economic evaluation to be a cost comparison rather than a true cost-minimisation analysis.
Submission history
Mar 2015: Not recommended · Authority Required
Jul 2015: Recommended with restriction · Authority Required